期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

二肽基肽酶-4抑制剂安全性的探讨

下载PDF
导出
摘要 糖尿病是高发非传染性慢性疾病，药物治疗是主要治疗手段，然而传统抗糖尿病药存在的低血糖、体质量增加、心血管事件风险增加等不良反应给降糖达标再添障碍，因此，以肠促胰素为治疗靶点的新型抗糖尿病药的安全性毫无疑问地成为探索热点。本文重点探讨抗糖尿病新药二肽基肽酶-4（dipeptidyl peptidase-4，DPP-4）抑制剂的安全性。
作者 邓昂 张相林
机构地区 中日友好医院药剂科
出处 《中国医院用药评价与分析》 2014年第10期867-870,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 制剂安全性 二肽基肽酶 抗糖尿病药 非传染性慢性疾病 药物治疗 体质量增加 心血管事件 不良反应
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献14

  • 1Vilsball T,AgersZ H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects [ J ]. J Clin Endocrinol Metab ,2003,88( 1 ) :220-224.
  • 2Freeman JS. Role of the incretin pathway in the patho- genesis of type 2 diabetes mellitus[J]. Cleve Clin J Med, 2009,76 ( Suppl 5 ) : S12-S19.
  • 3Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials : a position statement of the American Diabetes Association and 'a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association [ J ]. J Am Coll Cardiol, 2009,53 ( 3 ) :298-304.
  • 4Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment [ J ]. Pharmacol Rev, 2008,60(4) :470-512.
  • 5Feng J,Zhang Z,Wallace MB,et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase 1V ~ J J. J Med Chem, 2007,50 ( l0 ) : 2297 -2300.
  • 6孟艳秋,张宇,刘凤鑫,刘文虎,庞舒月.二肽基肽酶Ⅳ抑制剂的药理作用及其机制研究[J].现代药物与临床,2013,28(2):101-107. 被引量：11
  • 7Kirby M, Yu DM, OConnor S,et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition [J]. Clin Sci:Lond,2009 ,118(1 ) :31-41.
  • 8Kang NS, Ahn JH, Kim SS, et al. Docking-based 3D- QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors [ J]. Bioorg Med Chem Lett, 2007, 17 ( 13 ) : 3716-3721.
  • 9Baetta R, Corsini A. Pharmacology of dipeptidyl pepti- dase-4 inhibitors: similarities and differences[ J ]. Drugs, 2011,71 ( 11 ) : 1441-1467.
  • 10Yang W, Chen L, Ji Q, et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, rando- mized, double-blind, active control trial [ J ]. Diabetes Obes Metab ,2011,13 ( 1 ) :81-88.

二级参考文献60

  • 1欧阳凌云,杨刚毅.二肽基肽酶Ⅳ抑制剂治疗糖尿病的研究进展[J].国外医学（药学分册）,2006,33(2):111-113. 被引量：1
  • 2王璐,邸阜生.肠促胰岛素类似物和DPP-Ⅳ抑制剂在2型糖尿病治疗中的作用[J].医学综述,2007,13(1):25-27. 被引量：6
  • 3Cheng D. Prevalence, predisposition and prevention of type II diabetes [J]. Nutr Metab, 2005, (2): 29.
  • 4Gershell L. Type 2 diabetes market [J]. Nat Rev DrugDiscov, 2005, 4(5): 367-368.
  • 5Nauck M A, Heimesaat M M, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers [J]. J Clin Endoerinol Metab, 2002, 87(3): 1239-1246.
  • 6Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets [J]. Endocrinology, 2003, 144(12): 5149-5158.
  • 7Meier J J, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon- like peptide 1 in patients with type 2 diabetes [J]. J Clin EndocrinolMetab, 2003, 88(6): 2719-2725.
  • 8Verdich C, Flint A, Gutzwiller J P, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans [J]. J Clin Endocrinoz Metab, 2001, 86(9): 4382-4389.
  • 9Hinke S A, Gelling R W, Pederson R A, et al. Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insu- linotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats [J]. Diabetes, 2002, 51(3): 652-661.
  • 10Aertgeerts K, Ye S, Tennant M G, et al. Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation [J]. Protein Sci, 2004, 13(2): 412-421.

共引文献10

中国医院用药评价与分析
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部